JP2022518778A - 嚢胞性線維症の治療のための化合物および方法 - Google Patents

嚢胞性線維症の治療のための化合物および方法 Download PDF

Info

Publication number
JP2022518778A
JP2022518778A JP2021543157A JP2021543157A JP2022518778A JP 2022518778 A JP2022518778 A JP 2022518778A JP 2021543157 A JP2021543157 A JP 2021543157A JP 2021543157 A JP2021543157 A JP 2021543157A JP 2022518778 A JP2022518778 A JP 2022518778A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
mmol
lcms
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543157A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020160010A5 (cg-RX-API-DMAC7.html
Inventor
ピー． ザヴィストスキー，マイケル
オールマン，クリストファー
リー，フォン
コロジー，アンドリュー
モーニングスター，マーシャル
Original Assignee
フラットリー ディスカバリー ラブ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラットリー ディスカバリー ラブ，エルエルシー filed Critical フラットリー ディスカバリー ラブ，エルエルシー
Publication of JP2022518778A publication Critical patent/JP2022518778A/ja
Publication of JPWO2020160010A5 publication Critical patent/JPWO2020160010A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021543157A 2019-01-28 2020-01-28 嚢胞性線維症の治療のための化合物および方法 Pending JP2022518778A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797743P 2019-01-28 2019-01-28
US62/797,743 2019-01-28
US201962931502P 2019-11-06 2019-11-06
US62/931,502 2019-11-06
PCT/US2020/015441 WO2020160010A1 (en) 2019-01-28 2020-01-28 Compounds and methods for the treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
JP2022518778A true JP2022518778A (ja) 2022-03-16
JPWO2020160010A5 JPWO2020160010A5 (cg-RX-API-DMAC7.html) 2023-02-01

Family

ID=71841934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543157A Pending JP2022518778A (ja) 2019-01-28 2020-01-28 嚢胞性線維症の治療のための化合物および方法

Country Status (5)

Country Link
US (1) US20230055237A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917516A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022518778A (cg-RX-API-DMAC7.html)
CN (1) CN113613649A (cg-RX-API-DMAC7.html)
WO (1) WO2020160010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118050A1 (es) * 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
WO2022032062A1 (en) * 2020-08-06 2022-02-10 Carlex Glass America, Llc Method of attaching a connector to a glazing
EP4029500A1 (en) * 2021-01-15 2022-07-20 Universidad Autónoma de Madrid Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of nrf2-related diseases
RU2763141C1 (ru) * 2021-06-29 2021-12-27 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US20170204110A1 (en) * 2015-12-30 2017-07-20 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ585789A (en) * 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
US20170204110A1 (en) * 2015-12-30 2017-07-20 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIE, Y. M. ET AL: "Facile Synthesis of Functionalized Spiropyrrolizidine Oxindoles via a Three-Component Tandem Cycload", MOLECULES, vol. 16, no. 10, JPN6023052814, 2011, pages 8745 - 8757, XP055955857, ISSN: 0005373928, DOI: 10.3390/molecules16108745 *

Also Published As

Publication number Publication date
US20230055237A1 (en) 2023-02-23
EP3917516A1 (en) 2021-12-08
CN113613649A (zh) 2021-11-05
WO2020160010A1 (en) 2020-08-06
EP3917516A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
CN115557974A (zh) Kras g12d抑制剂及其应用
CN109069488B (zh) 乙型肝炎抗病毒剂
AU2011256380B2 (en) Macrocyclic compounds as Trk kinase inhibitors
CN104650068B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN118139855A (zh) 1,4-氧杂氮杂环庚烷衍生物及其用途
JP2022518778A (ja) 嚢胞性線維症の治療のための化合物および方法
CN112351780A (zh) Ptpn11的取代的杂环抑制剂
TW201639827A (zh) ＴＧＦ－β抑制劑
CN105705501A (zh) RORγ调节剂
CN115776891A (zh) Stat降解剂和其用途
CN107001316A (zh) 作为抗菌剂的喹诺酮衍生物
CN114786778A (zh) 治疗性化合物
CN117177744A (zh) Cdk2抑制剂及其使用方法
WO2023232130A1 (zh) 一种杂环化合物ccr4抑制剂及其用途
CN115515940A (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
WO2022184103A1 (zh) 三并环化合物及其药物组合物和应用
CN116157392A (zh) 靶向rna结合蛋白或rna修饰蛋白的化合物
CN104650070A (zh) 二氢嘧啶类化合物及其在药物中的应用
WO2023284651A1 (zh) N-(2-氨基苯基)苯甲酰胺类化合物及其应用
CN108779108A (zh) 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
CN115109061B (zh) 三环化合物
CN116354992A (zh) 一类pde4抑制剂及其在药物中的应用
TW202321256A (zh) ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途
CN114516873A (zh) 一种螺环类化合物、包含其药物组合物及其应用
WO2024175121A1 (zh) α，β-不饱和酰胺类化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230123

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723